Aurinia Pharmaceuticals Inc expected to post a loss of 2 cents a share - Earnings Preview

Aurinia Pharmaceuticals

11/02/2025 13:58

* Aurinia Pharmaceuticals Inc  AUPH.OQ   AUPH.O  is expected
to show a rise in quarterly revenue when it reports  results on
February 13 (estimated) for the period ending December 31 2024
    * The Edmonton Alberta-based  company is expected to report
a
32.9% increase in revenue to $59.945 million from $45.1 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Aurinia Pharmaceuticals
Inc is
for a loss of 2 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aurinia
Pharmaceuticals Inc is $11.00​, above​ its last closing price
of $7.97. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  0.02        0.02       0.10      Beat    566.7
 Jun. 30 2024  0.01        0.01       0.01      Met     20
 Mar. 31 2024  -0.18       -0.14      -0.03     Beat    78​
 Dec. 31 2023  -0.16       -0.16      -0.19     Missed  -16.3
 ​​Sep.        -0.16       -0.17      -0.09     Beat    46.2
 30 2023                                                
 Jun. 30 2023  -0.18       -0.18      -0.08     Beat    56.4​
 Mar. 31 2023  -0.22       -0.22      -0.18     Beat    18.7
 Dec. 31 2022  -0.27       -0.27      -0.18     Beat    34
 This summary was machine generated February 11 at 13:58 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)